ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025
Biosynthesis in Streptomyces sp. NRRL S-1813 and regulation between oxazolomycin A and A2.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A novel actinomycete strain, Streptomyces sp. NRRL S-1813 was employed to study its secondary metabolites under different mediums to activate its cryptic gene clusters and produce antimicrobial secondary metabolites. During fermentation optimization, and purification, oxazolomycin A and oxazolomycin A2 were isolated from one strain simultaneously. Their structure was elucidated using a series of characterization techniques, including full wavelength scanning, mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy. Oxazolomycin A2 was found not to be a typical enzymatic product of fermentation process. Instead, a spontaneous, non-enzymatic ring cleavage reaction was identified as mechanism for conversion of oxazolomycin A to oxazolomycin A2. Basing on these results, if the target product is oxazolomycin A2, the best fermentation condition of Streptomyces sp. NRRL S-1813 should be the Medium B under the alkalescence condition. For the biosynthesis of oxazolomycin A, the medium pH and reaction time were both important. A slightly acidic environment suppresses the side reactions such as hydrolysis of product, while reasonable reaction time minimizes accumulation of byproducts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.